000			01773nam a2200265Ia 4500
999			_c4080 _d4080
003			IN-GtHPI
005			20201107112547.0
008			191113b ii ||||| |||| 00| 0 eng d
020			_a9812707786
082			_221 _a615.39 _bCHA/A
100			_aChang, Thomas Ming Swi. _eaut
245		0	_aArtificial cells _bbiotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/stem cell therapy _cby Thomas Ming Swi Chang.
260			_aHackensack, N. J _bWorld Scientific Publishing Co. Pte. Ltd. _cc2007
300			_axxvi, 455p. _bill. (some col.) _c24cm.
490			_aRegenerative medicine, artificial cells and nanomedicine _vv.1
500			_aIncludes bibliographical references (p. 377-440) and index.
505			_a50th anniversary of artificial cells -- Basic principles -- Oxygen carriers based on nanobiotechnology -- A nanobiotechnologic therapeutic that transports oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions -- Nanotechnology-based artificial red blood cells (RBC's) -- Use of enzyme artificial cells for genetic enzyme defects that increase systemic substrates to toxic levels -- Enzyme artificial cells in substrate-dependent tumors and activation of prodrug -- Artificial cells for cell encapsulation -- Artificial cells containing hepatocytes and/or stem cells in regenerative medicine -- Hemoperfusion in poisoning, kidney failure, liver failure, and immunology -- Perspectives on the future of artificial cells as suggested by past research.
650		0	_aPharmaceutical Microbiology _918
650		0	_aBiology _922
650		0	_aArtificial cells _9332
650		0	_aBlood substitutes _9333
650		0	_aBiotechnology _9187
650		0	_aPharmaceutics _915
942			_2ddc _cREF